Paper Details

  1. Home
  2. Paper Details

MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma.

Author: , CaldonCatherine E, CastilloLesley, ChouAngela, DengNiantao, Gallego-OrtegaDavid, JohnsAmber, LawAndrew M K, LucasMorghan C, MawsonAmanda, MurphyKendelle J, NessemDanielle, OakesSamantha R, OrmandyChristopher J, PajicMarina, ParkinAshleigh, SchafranekPia, SteinmannAngela M, TimpsonPaul, YoungAdelaide I J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Targeting both MCL-1 and SRC proteins in pancreatic ductal adenocarcinoma (PDAC) may be a promising therapeutic strategy. This study shows that combining an MCL-1 antagonist with the SRC inhibitor dasatinib reduces tumor growth and metastasis in preclinical models.
Paper Details　
Original Abstract of the Article :
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies. It is phenotypically heterogeneous with a highly unstable genome and provides few common therapeutic targets. We found that MCL1, Cofilin1 (CFL1) and SRC mRNA were highly expressed by a wide range of these cancers, su...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033042/

データ提供：米国国立医学図書館（NLM）

MCL-1 Antagonism: A New Strategy to Combat Pancreatic Cancer

This research investigates the potential of MCL-1 antagonism, a strategy that targets the MCL-1 protein, in combination with dasatinib, a drug that inhibits SRC kinase, to treat pancreatic ductal adenocarcinoma (PDAC), a highly aggressive and difficult-to-treat cancer. It's like discovering a new weapon in the desert of cancer treatment, where MCL-1 antagonism offers a potential solution to overcome drug resistance and enhance the effectiveness of current therapies. The researchers found that MCL-1 antagonism synergized with dasatinib to reduce cell viability and invasiveness in PDAC cells.

MCL-1 Antagonism: A Powerful Ally in the Fight Against Pancreatic Cancer

The study demonstrated that MCL-1 antagonism synergized with dasatinib to reduce cell viability and invasiveness in PDAC cells. It's like discovering a hidden oasis in the desert of cancer treatment, where MCL-1 antagonism provides a source of water to combat the relentless growth of this deadly disease. This finding suggests that MCL-1 antagonism could be a valuable new strategy to improve the treatment of PDAC.

Navigating the Desert of Pancreatic Cancer Treatment: New Hope on the Horizon

This research highlights the potential of MCL-1 antagonism as a novel therapeutic target for PDAC. It's like discovering a new pathway through the desert of pancreatic cancer treatment, where MCL-1 antagonism offers a promising alternative to current therapies. This study underscores the importance of ongoing research and development of innovative treatment strategies to combat this devastating disease.

Dr.Camel's Conclusion

This research presents a compelling case for the use of MCL-1 antagonism in combination with dasatinib to treat pancreatic cancer. It's like discovering a new weapon in the desert of cancer treatment, where MCL-1 antagonism offers a potential solution to overcome drug resistance and enhance the effectiveness of current therapies. This study offers hope for a future where new treatment strategies, like MCL-1 antagonism, can provide better outcomes for patients with this challenging disease.

Date :
  1. Date Completed 2020-11-24
  2. Date Revised 2023-11-03
Further Info :

Pubmed ID

31735913

DOI: Digital Object Identifier

PMC7033042

Related Literature

Article Analysis
・Effects of dasatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.